Donna Neuberg

Boston University — United States

Medicine · Health Sciences

155h-index100.7kcitations1.7kworks3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(378), Acute Myeloid Leukemia Research(315), Acute Lymphoblastic Leukemia research(284), Lymphoma Diagnosis and Treatment(261), Cancer Genomics and Diagnostics(170)

Publications1.7k total

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
The LMO2-LDB1-TAL1 complex regulates transcription networks in acute myeloid leukemia
Blood Neoplasia·2025Open Access
Supplemental Table S6 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
2025Open Access
Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
Supplemental Fig. S2 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
2025Open Access
Table S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
Supplemental Table S5 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
2025Open Access
Table S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
Supplemental Table S3 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
2025Open Access
Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
Supplemental Table S4 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
2025Open Access
Supplemental Table S7 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
2025Open Access
Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
Supplemental Fig. S3 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
2025Open Access
Supplemental Table S2 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
2025Open Access
Table S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
Supplemental Table S1 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
2025Open Access
Supplemental Fig. S1 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
2025Open Access
page 1 of 85Next →

Frequent Co-authors

Benjamin L. Ebert(11), Gad Getz(10), Stacey Gabriel(9), Catherine J. Wu(9), Scott J. Rodig(7), Eric S. Lander(7), Nir Hacohen(7), Sachet A. Shukla(6), Wandi Zhang(6), Kristen E. Stevenson(6), R. Coleman Lindsley(5), Shuqiang Li(5), Margaret A. Shipp(5), Todd R. Golub(5), Matthew Meyerson(5), Brenton G. Mar(4), Patrick A. Ott(4), Derin B. Keskin(4), Jerome Ritz(4), Edward F. Fritsch(4)